Treatment of ulcerative colitis AbbVie JAK inhibitors reaches phase 3 clinical end

AbbVie today announced that its JAK inhibitor, upadacitinib, has reached the primary endpoint of clinical remission and all critical secondary endpoints in Phase 3 clinical trials for adult patients treating moderate ulcerative colitis.
in the 8th week of treatment, 26 percent of patients in the upadacitinib group achieved clinical remission, and the placebo group had a 5 percent (p.lt;0.001).
ulcerative colitis is a chronic, systemic, inflammatory disease caused by inflammation of the large intestine, which causes abdominal pain, bloody diarrhea, severe detox, weight loss and fatigue.
the severity of the symptoms and the uncertainty of the recurrence of the disease put a heavy burden on the patient and often led to disability.
, discovered and developed by AbbVie scientists, is a daily oral, selective and reversible JAK inhibitor.
August 2019, it was approved by the U.S. FDA to treat adult patients with moderate to severe active rheumatoid arthritis who did not respond to or were insatiable with methotrexate.
the JAK protein family mediated a variety of inflammatory factors signaling.
, upadacitinib is currently evaluated in a number of clinical trials for a variety of inflammatory diseases such as endexual dermatitis, Crohn's disease, psoriasis arthritis, and more.
results showed that, in addition to reaching the primary endpoint, more patients (36%) in the upadacitinib group achieved endoscopy improvement in week 8 than in the placebo group (7%).
, patients treated with upadacitinib received a higher proportion of clinical responses in week 8 (73% vs. 27% ;p-lt;0.001).
results of the Phase 3 clinical trial of Upadacitinib (Photo: Source: References) Reference: 1 . . . Upadacitinib (RINVOQ™) Meets Primary and All Ranked Secondary Endpoints in First Phase 3 Induction Study in Ulcerative Colitis Colitis. Retrieved December 9, 2020, from